How can post-COVID care be improved using patient experiences with received care and perceived health? A qualitative study of focus groups with 30 patients having post-COVID in the Netherlands.

How can post-COVID care be improved using patient experiences with received care and perceived health? A qualitative study of focus groups with 30 patients having post-COVID in the Netherlands.

Publication date: Sep 21, 2025

To provide bottom-up guidance on improving post-COVID care using patients’ experiences with received care and their perceived health DESIGN: Qualitative study design using focus group interviews PARTICIPANTS: 30 patients with post-COVID condition recruited through purposive sampling based on patient complexity and diversity RESULTS: Three dimensions for potential improvements of post-COVID care were identified: (1) building, supporting and maintaining patient resilience, (2) redesigning healthcare pathways to meet patient needs and (3) embedding post-COVID care in health systems and organisations. A conceptual framework that could guide improvements in post-COVID care was developed. This study revealed several opportunities for improving and implementing post-COVID care following a person-centred approach in multidisciplinary integrated care pathways with an integrative vision of health.

Open Access PDF

Concepts Keywords
Covid Adult
Healthcare Aged
Improved Chronic Disease
Netherlands COVID-19
Therapy COVID-19
Female
Focus Groups
Humans
Male
Middle Aged
Netherlands
Patient Satisfaction
Post-Acute COVID-19 Syndrome
Post-Acute COVID-19 Syndrome
Qualitative Research
Resilience, Psychological
SARS-CoV-2

Semantics

Type Source Name
disease MESH post-COVID condition
drug DRUGBANK Coenzyme M
disease MESH COVID 19
disease MESH infection
disease MESH syndrome
drug DRUGBANK Trestolone
drug DRUGBANK Indoleacetic acid
disease MESH Chronic Conditions
disease IDO algorithm
disease MESH pulmonary diseases
disease MESH educational status
disease IDO process
disease MESH relapse
disease MESH functional status
drug DRUGBANK Tropicamide
disease MESH post traumatic stress disorder
disease MESH infectious diseases
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH kinesiophobia
disease MESH uncertainty
disease MESH Q fever
disease MESH chronic fatigue syndrome
pathway REACTOME Translation
drug DRUGBANK Human vaccinia virus immune globulin
disease MESH neck cancer
disease MESH morbidity
drug DRUGBANK ATP
disease IDO intervention
drug DRUGBANK Pentaerythritol tetranitrate

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *